Study suggests new hope for pulmonary hypertension
Halo Biosciences has announced publication of results in Thorax from the Phase IIa SATURN study for patients with pulmonary hypertension and interstitial lung disease (PH-ILD).
The study, conducted at Stanford University, evaluated 4-methylumbelliferone (4-MU) in patients with pulmonary hypertension, a highly progressive disease with significant unmet needs. The Phase IIa randomised, double-blind, placebo-controlled trial enrolled 16 patients with pulmonary hypertension.
Promising clinical signals
4-MU was safe and well-tolerated throughout the 24-week treatment period. The primary haemodynamic measurement of change in pulmonary vascular resistance was not statistically significant. Among patients with PH-ILD, prespecified exploratory efficacy signals showed a mean improvement of 66 metres in six-minute walk
distance and enhanced quality-of-life scores. These findings support further clinical evaluation of 4-MU as a potential disease-modifying therapy for inflammatory and fibrotic lung diseases.
“These clinical data reinforce the scientific rationale for targeting hyaluronan in fibrotic and inflammatory lung disease and highlight 4-MU’s potential as a first-in-class, disease-modifying extracellular matrix (ECM)-modulator for patients with serious conditions like PH-ILD,” said Paul Bollyky, Professor of Medicine at Stanford University and Scientific Co-founder of Halo Biosciences. “This represents a meaningful step forward for individuals living with PH-ILD, a condition with limited treatment options and a high burden of disease.”
HB-1614, Halo’s lead investigational therapy, is a proprietary, oral formulation of 4-MU optimised for improved bioavailability and long-term use in patients with chronic lung conditions such as PH-ILD. By inhibiting hyaluronan synthesis, HB-1614 targets a key driver of ECM remodelling involved in inflammation and fibrosis—processes central to disease progression in several debilitating diseases, including PH-ILD.
“We are proud to see the SATURN study featured in Thorax, validating our translational approach and marking a key milestone in our development of HB-1614,” said Anissa Kalinowski, Chief Executive officer of Halo Biosciences. “We are thankful to Stanford University and sponsor investigators Roham Zamanian and Vinicio de Jesus Perez for their leadership of the SATURN trial, unlocking the potential of this new mechanism of action.”
Halo Biosciences is progressing clinical development of HB-1614 and exploring partnership opportunities to accelerate its work in PH-ILD and other fibrotic conditions. The company holds exclusive intellectual property for its formulation and is positioned to optimise drug delivery, bioavailability and regulatory strategy.
Megan Thomas, Multimedia Editor, DDW
